[at TheStreet] – Gilead’s decision to price Sovaldi at $84,000 per treatment may open door for competitors like Abbvie to gain market share from cost-conscious pharmacy benefits managers.
Read more on this.
Gilead … [visit site to read more]
Similar posts:- Company Update – AbbVie Inc. (NYSE:ABBV) – European drug trial secrecy case hit by delay
- Stock Update: Express Scripts Holding Company (NASDAQ:ESRX) – Moody’s: Formulary exclusions credit negative for branded drug makers
- International Business Machines Corporation (NYSE:IBM) ~ IBM to launch cheaper, more powerful Watson, NY Times says
